e-learning
resources
Virtual 2021
05.09.2021
Airway pharmacology: translational and basic science
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients
I. Schouten (Leiden (ZH), Netherlands), A. Van Der Linden (Leiden (ZH), Netherlands), P. Hiemstra (Leiden (ZH), Netherlands), R. Mumford (Leiden (ZH), Netherlands), J. Stolk (Leiden (ZH), Netherlands)
Source:
Virtual Congress 2021 – Airway pharmacology: translational and basic science
Session:
Airway pharmacology: translational and basic science
Session type:
E-poster
Number:
554
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
I. Schouten (Leiden (ZH), Netherlands), A. Van Der Linden (Leiden (ZH), Netherlands), P. Hiemstra (Leiden (ZH), Netherlands), R. Mumford (Leiden (ZH), Netherlands), J. Stolk (Leiden (ZH), Netherlands). Effect of intravenous alpha-1-antitrypsin augmentation therapy on proteinase-3-generated AaVal541 in deficient patients. 554
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Efficacy of augmentation therapy for emphysema associated with alpha1-antitrypsin deficiency: enough is enough
Source: Eur Respir J 2016; 47: 35-38
Year: 2016
Effect of augmentation therapy on immune function of patients with severe Alpha1-antitrypsin deficiency
Source: Annual Congress 2012 - COPD treatments: efficacy and safety
Year: 2012
Long-term effect of alpha-1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients
Source: Virtual Congress 2021 – Treatments for airway diseases
Year: 2021
Effect of corticosteroid therapy upon serum magnesium level in chronic asthmatic children
Source: Annual Congress 2010 - Paediatric asthma, rhinitis and management
Year: 2010
Effect of high dose alpha-1-antitrypsin infusion on neutrophil-generated fibrinogen fragments in type Z alpha-1-antitrypsin deficient patients
Source: Eur Respir J 2004; 24: Suppl. 48, 307s
Year: 2004
Impact of alpha 1-antitrypsin deficiency and prior augmentation therapy on patients' survival after lung transplantation
Source: Eur Respir J, 50 (3) 1700962; 10.1183/13993003.00962-2017
Year: 2017
Oral corticosteroid treatment reduces serum chitotriosidase activity in patients with COPD
Source: Annual Congress 2010 - COPD: treatment and monitoring
Year: 2010
The withdrawal of replacement therapy and outcomes in alpha-1 antitrypsin deficiency lung transplant recipients
Source: Eur Respir J, 53 (5) 1900055; 10.1183/13993003.00055-2019
Year: 2019
The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients
Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases
Year: 2010
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
Effect of discontinuation and readministration of inhaled human insulin on pulmonary safety in adult diabetes patients
Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology
Year: 2007
Influence of protein C activity on the PT/INR in patients receiving heparin
Source: Eur Respir J 2003; 22: Suppl. 45, 221s
Year: 2003
Effect of oral N-acetylcysteine treatment on systemic inflammatory status in COPD patients
Source: Eur Respir J 2005; 26: Suppl. 49, 716s
Year: 2005
Comparison of efficacy of intravenous and inhaled magnesium sulphate as an adjunct to standard therapy in acute severe asthma
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008
Homecare setting of longterm augmentation therapy in alpha1 antitrypsin defiency patients leads to clinical stabilization
Source: International Congress 2017 – New frontiers in home care management of chronic lung diseases
Year: 2017
Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease.
Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Year: 2019
Influence of a combination therapy
versus
steroid monotherapy on FeNO
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009
Pulmonary administration of alpha
1
-antitrypsin for the treatment of Alpha
1
-antitrypsin deficiency
Source: Eur Respir J 2003; 22: Suppl. 45, 385s
Year: 2003
Effect of systemic steroid treatment on serum leptin levels in patients with COPD exacerbation
Source: Eur Respir J 2005; 26: Suppl. 49, 284s
Year: 2005
Long-term experience in the treatment of alpha 1-antitrypsin deficiency: 25 years of augmentation therapy
Source: Eur Respir Rev 2015; 24: 46-51
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept